Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CMO Robert Iannone Sells 2,403 Shares of Stock

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CMO Robert Iannone sold 2,403 shares of Jazz Pharmaceuticals stock in a transaction on Monday, March 10th. The stock was sold at an average price of $138.41, for a total transaction of $332,599.23. Following the sale, the chief marketing officer now owns 79,621 shares of the company’s stock, valued at $11,020,342.61. The trade was a 2.93 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Robert Iannone also recently made the following trade(s):

• On Friday, March 7th, Robert Iannone sold 7,080 shares of Jazz Pharmaceuticals stock. The shares were sold at an average price of $138.60, for a total transaction of $981,288.00.

Jazz Pharmaceuticals Stock Down 2.0 %

Shares of NASDAQ:JAZZ opened at $134.16 on Thursday. The stock has a market cap of $8.15 billion, a P/E ratio of 18.90, a P/E/G ratio of 1.04 and a beta of 0.44. The firm has a fifty day moving average price of $128.92 and a 200 day moving average price of $120.49. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. Jazz Pharmaceuticals plc has a 1-year low of $99.06 and a 1-year high of $148.06.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Needham & Company LLC restated a “buy” rating and set a $210.00 price target on shares of Jazz Pharmaceuticals in a research report on Wednesday, March 5th. Barclays reaffirmed an “overweight” rating and set a $200.00 target price (up from $190.00) on shares of Jazz Pharmaceuticals in a research note on Thursday, February 27th. Morgan Stanley reissued an “overweight” rating and issued a $183.00 price objective (up from $175.00) on shares of Jazz Pharmaceuticals in a research report on Friday, March 7th. Piper Sandler reissued an “overweight” rating and issued a $176.00 price objective (up from $163.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, February 26th. Finally, UBS Group raised shares of Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their price objective for the company from $145.00 to $179.00 in a research report on Friday, March 7th. One equities research analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $190.53.

Institutional Trading of Jazz Pharmaceuticals

Large investors have recently bought and sold shares of the business. IFP Advisors Inc acquired a new stake in Jazz Pharmaceuticals during the 4th quarter worth $25,000. Quadrant Capital Group LLC raised its position in Jazz Pharmaceuticals by 97.1% during the 4th quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company’s stock worth $25,000 after buying an additional 101 shares during the last quarter. Elequin Capital LP raised its position in Jazz Pharmaceuticals by 677.8% during the 4th quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company’s stock worth $26,000 after buying an additional 183 shares during the last quarter. CoreFirst Bank & Trust purchased a new position in Jazz Pharmaceuticals during the 4th quarter worth $28,000. Finally, Allianz SE purchased a new position in Jazz Pharmaceuticals during the 4th quarter worth $29,000. Institutional investors and hedge funds own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.